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Disruption of TNF-a/TNFR1 Function in Resident
Skin Cells Impairs Host Immune Response
against Cutaneous Vaccinia Virus Infection
Tian Tian1, Krista Dubin2, Qiushuang Jin3, Ali Qureshi4, Sandra L. King1, Luzheng Liu1, Xiaodong Jiang1,
George F. Murphy5, Thomas S. Kupper1 and Robert C. Fuhlbrigge1,6
One strategy adopted by vaccinia virus (VV) to evade the host immune system is to encode homologs of TNF
receptors (TNFRs) that block TNF-a function. The response to VV skin infection under conditions of TNF-a
deficiency, however, has not been reported. We found that TNFR1/ mice developed larger primary lesions,
numerous satellite lesions, and higher skin virus levels after VV scarification. Following their recovery, VV-
scarified TNFR1/ mice were fully protected against challenge with a lethal intranasal dose of VV, suggesting
these mice had developed an effective memory immune response. A functional systemic immune response was
further demonstrated by enhanced production of VV-specific IFN-g and VV-specific CD8þ T cells in spleens and
draining lymph nodes. Interestingly, bone marrow (BM)–reconstitution studies using wild-type (WT) BM in
TNFR1/ host mice, but not TNFR1/ BM in WT host mice, reproduced the original results seen in TNFR1/
mice, indicating that TNFR1 deficiency in resident skin cells, rather than hematopoietic cells, accounts for the
impaired cutaneous immune response. Our data suggest that lack of TNFR1 leads to a skin-specific immune
deficiency, and that resident skin cells have a crucial role in mediating an optimal immune defense to VV
cutaneous infection via TNF-a/TNFR1 signaling.
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INTRODUCTION
Vaccinia virus (VV) is a large double-stranded DNA virus
belonging to the poxvirus family. Like other poxviruses, VV
has evolved elegant and sophisticated mechanisms to evade
detection and destruction by the host immune system. One of
the evasion strategies adopted by VV is to encode homologs
of cytokines, chemokines, and their receptors that have crucial
roles in control of the immune response (Seet et al., 2003).
As TNF-a is a potent inflammatory cytokine that can
orchestrate communication between innate and adaptive
immune responses, it is not surprising that VV has developed
mechanisms to interfere with the TNF-a/TNF receptor (TNFR)
pathway. The best-characterized anti-TNF-a strategy em-
ployed by VV is to encode homologs of TNFR, termed
vTNFR, that can bind and sequester TNF-a (Reading et al.,
2002). In contrast, recombinant VV expressing the gene for
murine TNF-a demonstrated attenuated virulence in vivo
(Sambhi et al., 1991).
Within the normal host, TNF-a is produced principally by
macrophages and activated T cells. TNF-a–mediated effects
are critically important in the response to a variety of
infections caused by bacteria, protozoa, fungi, and viruses
(Schluter and Deckert, 2000). For VV in particular, it has been
reported that mice deficient in TNF-a or TNFRs are more
susceptible to intraperitoneal and intravascular infections
(Ruby et al., 1997; Nie et al., 2009). The mechanism and
outcome of cutaneous VV infection is not necessarily
expected to be the same as these systemic infections and
the role of TNF-a following cutaneous infection is less well
defined. Although routine vaccination against smallpox was
discontinued in the United States in 1972, the potential for
use of the smallpox virus as a bioterror agent and the endemic
presence of monkeypox virus in Africa has resulted in
continued use of smallpox vaccines in medical, military,
and at-risk populations (Rimoin et al., 2010). Effective
smallpox vaccination in humans is commonly achieved by
inoculating skin with live VV by scarification. Inoculation via
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other routes, or use of killed virus vaccines, is known to result
in inferior protective responses in humans (McClain et al.,
1997). We have also demonstrated that VV scarification
elicits stronger T-cell and humoral responses, compared with
other routes of immunization in mice (Liu et al., 2010).
However, smallpox vaccination by scarification can lead to
uncontrolled virus replication, known as eczema vaccina-
tum, in patients with atopic dermatitis and immune defi-
ciency disorders, resulting in devastating morbidity and
mortality (Engler et al., 2002).
This study explores the impact of TNF-a/TNFR1 deficiency
on the outcome of cutaneous VV infection. After VV
scarification, TNFR1/ mice demonstrated an impaired
cutaneous immune response with a phenotype that re-
sembled eczema vaccinatum. Investigation of innate and
adaptive immune responses in TNFR1/ mice showed no
difference in effector or memory immune responses. The
results of bone marrow (BM) reconstitution studies suggest
that the impaired cutaneous response was caused by TNFR1
deficiency of resident skin cells.
RESULTS
TNFR1-deficient mice developed markedly larger skin lesions
with higher virus counts compared with wild-type (WT) mice
following VV scarification
Mice were scarified with WR-VV at the base of the tail and
observed for the development of pox lesions. Seven days after
VV scarification, TNFR1/ mice exhibited lesions that were
at least 2-fold larger than lesions on WT control mice. At day
14, the differences in skin lesions were more dramatic, as
multiple satellite lesions appeared on the TNFR1/ mice
and the lesions on WT mice started to heal. By day 21,
TNFR1/ mice showed signs of skin healing, but
their lesions were still markedly larger than WT controls
(Figure 1a–c). To confirm the effect of TNF-a on skin lesions,
WT mice were treated with function-blocking anti-TNF-a
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Figure 1. TNF receptor (TNFR)1/ mice developed markedly larger skin lesions with higher virus counts following vaccinia virus (VV) scarification.
5 106 pfu of WR-VV was applied to the base of the tail by scarification for all studies. At indicated time points, (a) photographs were taken and (b) skin lesions
were measured. (c) Numbers of satellite lesions were recorded on day 14. (d) Wild-type (WT) mice were treated with anti-TNF-a or control antibody before
and following VV scarification, and lesion size was measured. VV DNA copy number was determined by quantitative PCR in (e) inoculated and (f) adjacent
skin following VV scarification. Error bars represent mean±SEM. n¼5 per group. *Po0.05, **Po0.01, ***Po0.001. Ab, antibody; NS, not significant.
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mAb or control antibody (Ab). Anti-TNF-a mAb treatment led
to significantly larger lesions in WT mice following VV
scarification, consistent with the results seen in TNFR1/
mice (Figure 1d). In both studies, all mice ultimately survived
and skin lesions resolved by day 28–35. These data indicate
that disruption of the TNF-a/TNFR1 pathway leads to
exacerbation of skin lesions following VV scarification.
To investigate whether the enhanced skin lesions were
associated with virus replication and dissemination, we
measured the virus load of inoculated tail skin and skin
adjacent to the pox lesion. We found that TNFR1/ and WT
mice possessed comparable levels of virus in inoculated skin
1 week after VV scarification. At 2 weeks after scarification,
TNFR1/ mice had slightly higher virus loads in the
inoculated skin than WT controls (Figure 1e). In contrast,
analysis of skin samples adjacent to scarification sites
revealed that the skin of TNFR1/ mice contained at least
100-fold more virus than that of WT mice 1 week after
VV scarification and 10 times more virus 2 weeks after
scarification (Figure 1f). Thus, TNFR1/ mice have a defect
in controlling local VV replication and dissemination, which
might contribute to the formation of larger skin lesions.
To investigate whether the impaired cutaneous response
of TNFR1/ mice to VV scarification reflected a global
impairment or a skin-specific immune dysfunction, we
measured viral load in peripheral organs, and found that
TNFR1/mice and WT mice had comparable viral burdens
in inguinal lymph node (ILN), spleen, lung, and liver for up to
2 weeks post scarification and both cleared VV from
peripheral organs by 3 weeks (Supplementary Figure S1
online). The impaired host response of TNFR1/ mice to
VV scarification, therefore, appears to be restricted to skin.
Humoral immune response was reduced in TNFR1/ mice
following VV scarification, although survival from intranasal
challenge was not affected
To investigate the mechanisms underlying the impaired
cutaneous response of TNFR1/ mice after VV scarification,
we compared the production of VV-specific Ab between
TNFR1/ and WT mice following VV scarification. Total
VV-specific IgG levels in TNFR1/ mice were similar to
those in WT mice up to 3 weeks after VV scarification but
significantly less than those in WT mice at 4 weeks and later.
Interestingly, TNFR1/mice did not generate significant VV-
specific IgG1 at any time point, yet their production of IgG2a
was comparable to WT controls (Figure 2a). These results
indicate that the humoral immune response in TNFR1/
mice was impaired following VV scarification. However, the
observation that TNFR1/ and WT mice produced compar-
able levels of VV-specific Ab during 2 weeks following
scarification indicates that the difference in lesion size and
character seen in TNFR1/ mice was not caused by inferior
VV-specific Ab production. To confirm generation of systemic
immunity, we challenged TNFR1/ and WT mice 6 weeks
after VV scarification with a lethal intranasal dose of WR-VV.
All of the immunized mice survived the challenge while
unimmunized mice lost body weight at the same rate and died
within 1 week (Figure 2b). Thus, the reduced humoral
response did not impair systemic immune protection to
subsequent lethal challenge in TNFR1/ mice.
Type 1 T-cell immune response was enhanced in TNFR1/
mice following VV scarification
To determine whether the altered cutaneous response of
TNFR1/ mice was due to a defect in T-cell immune
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Figure 2. The altered vaccinia virus (VV)-specific antibody response observed in TNF receptor (TNFR)1/ mice following scarification did not affect
survival of immunized mice challenged with intranasal VV. (a) 5 106 pfu of WR-VV was applied to TNFR1/ and wild-type (WT) mice by scarification.
The level of VV-specific antibody in the sera of individual mice was measured by ELISA. (b) Six weeks after scarification, TNFR1/ and WT mice were
challenged with 2 106 pfu of WR-VV by intranasal inoculation. Naive TNFR1/ and WT were used as controls. The body weight and survival of the
mice were recorded daily and plotted. Error bars represent mean±SEM. n¼5 per group. Representative results of three independent experiments are shown.
*Po0.05, **Po0.01, ***Po0.001. OD, optical density.
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responses, we used in vitro restimulation assays to detect
VV-specific cytokine production and VV B8R2027 peptide
(TSYFESV)/MHC pentamer staining to enumerate VV-specific
CD8þ T cells in spleens and ILNs. Similar levels of
VV-induced IFN-g were produced by spleen cells from
TNFR1/ and WT mice 7 days following WR-VV scarifica-
tion. Surprisingly, by days 14 and 30, the level of IFN-g
secreted by spleen cells from TNFR1/ mice was signifi-
cantly higher than that for WT mice. ILN cells from VV-
scarified TNFR1/ mice produced significantly more IFN-g
than WT ILN cells at all observed time points (Figure 3a). No
significant production of IL-4 or IL-10 was detected from the
spleen or ILN cells of VV-inoculated mice of either strain
(data not shown).
Consistent with the results of in vitro restimulation assays,
spleens of TNFR1/mice contained similar numbers of VV-
specific CD8þ T cells as compared with WT mice at day 7
post scarification. At days 14 and 30, TNFR1/ mice had
significantly more VV-specific CD8þ T cells evident in the
spleen. TNFR1/ mice displayed a greater number of VV-
specific CD8þ T cells in the ILN at all observed time points
(Figure 3b and c). These data suggest TNFR/ mice are not
deficient in production of CD8þ effector cells.
To address the possibility that the increased Th1 response
in TNFR1/ mice could be due to greater antigen levels,
resulting from the higher virus counts in the skin, we scarified
mice with modified vaccinia ankara (MVA), a strain of VV
that does not replicate in mammalian cells. As seen with VV,
spleen cells of MVA-scarified TNFR1/ mice produced
similar levels of IFN-g at day 7 and higher levels at
days 14 and 30 when compared with WT mice. ILN cells
of TNFR1/ mice also produced more IFN-g than WT mice
at day 7 (Figure 3d). These results indicate that the enhanced
Th1 cytokine production observed in TNFR1/ mice is
independent of antigen load. Furthermore, lesion size was
similar between TNFR1/ and WT mice following MVA
scarification (data not shown), suggesting that the larger
lesions and satellite lesions observed in TNFR1/mice after
VV scarification reflect the cytopathic effect of replicating
VV. Collectively, these data indicate that the altered
cutaneous response of TNFR1/ mice following VV
scarification was not caused by a defect of T-cell activation,
production of VV-specific CD8þ effector cells, or Th1 helper
response. In fact, TNFR1/ mice had an enhanced type 1
T-cell response as compared with WT mice.
T-cell homing to the inoculation site was not altered by TNFR1
deficiency
The impaired cutaneous response of TNFR1/ mice might
indicate a defect in T-cell homing to skin following VV
scarification. However, comparable CD3þ T-cell infiltration
was found in the lesions of TNFR1/ mice and WT mice 6
days post VV scarification (Figure 4a). To assess the kinetics
of T-cell skin homing, we performed FACS analysis on cells
recovered from tail skin at different time points following VV
scarification and found similar ratios of CD4þ and CD8þ
T cells recruited to the inoculated skin of TNFR1/ and WT
mice (Figure 4b). Given that the total number of skin cells
recovered was slightly higher in TNFR1/ mice than WT
mice (data not shown), these results suggest that TNFR1/
mice could recruit CD4þ and CD8þ T cells to skin at least as
efficiently as WT mice.
To further explore the influence of TNFR1 deficiency on
VV-specific CD8þ T-cell skin homing, we also performed
B8R-pentamer staining. At day 3 post VV scarification, very
few CD8þ T cells were present in the inoculated skin of
either TNFR1/ or WT mice (Figure 4c). At day 7, both
TNFR1/ and WT had substantial numbers of CD8þ T cells
present in the inoculation site, with a similar fraction of
CD8þ T cells staining with B8R pentamer (TNFR1/: 18.7%;
WT: 19.5%) (%B8R within CD8þ ¼%B8RþCD8þ /(% total
CD8þ )100). On days 14 and 30, TNFR1/mice continued
to show slightly higher %B8Rþ CD8þ T cells than WT controls.
Alternative explanations for the impaired cutaneous
immune response in TNFR1/ mice could reflect enhanced
recruitment of regulatory T cells to the site of inoculation
(Rouse et al., 2006) or altered functions of the VV-specific
CD8 effector cells present in the site. We found the fraction of
CD4þCD25þFoxP3þ regulatory T cells in inoculated skin
were comparable in WT and TNFR1/ mice (23.4% and
22.6%, respectively) (Supplementary Figure S2a online).
Furthermore, CD8þB8Rþ T cells from TNFR1/ mice
produced similar levels of IFN-g and granzyme B in response
to in vitro stimulation as compared with WT mice (Supple-
mentary Figure S2b and c online). These results suggest that
VV-specific CD8þ T cells recruited to the inoculated skin are
not defective or suppressed, and general T-cell homing to the
skin is operational in TNFR1/ mice following VV
scarification.
Impaired cutaneous response to VV scarification is associated
with TNFR1 deficiency of resident skin cells and not of
BM–derived hematopoietic cells
The development of pox lesions in VV-scarified mice
involves both BM-derived cells that are recruited to the skin
as well as skin stromal cells, including keratinocytes and
fibroblasts. To distinguish which of these two cell populations
utilized TNF-a/TNFR1 signaling to control virus dissemina-
tion and skin lesion formation, we generated three groups of
chimeric mice: (1) TNFR1/ BM-WT host, (2) WT BM-
TNFR1/ host, and (3) WT BM-WT host. Chimeric mice
were inoculated with VVB8 weeks after irradiation and BM
reconstitution. By day 12 after VV scarification, WT BM-
TNFR1/ mice developed multiple satellite lesions and had
significantly larger lesions than both WT BM-WT and
TNFR1/ BM-WT mice (Figure 5a), a phenotype that is
strikingly similar to that of non-irradiated/non-reconstituted
TNFR1/ mice.
Assessment of viral load in lesional and adjacent skin
confirms the gross impression. VV DNA copy number was
similar within lesional skin of all three chimeric mouse
populations. Assessment of adjacent skin, however,
shows high viral load in WT BM-TNFR1/ mice while
TNFR1/ BM-WT and WT BM-WT chimeric
mice contained only trace amounts of virus (Figure 5b). From
these data, we conclude that the lack of TNFR1 in
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Figure 3. Type 1 T-cell immune response was enhanced in TNF receptor (TNFR)1/ mice following vaccinia virus (VV) scarification. 5 106 pfu of
WR-VV was applied to TNFR1/ and wild-type (WT) mice by scarification. At indicated time points, spleens and inguinal lymph nodes (ILNs) were
harvested for (a) in vitro restimulation to detect VV-specific IFN-g and (b) B8R-pentamer staining to identify VV-specific CD8þ T cells. (c) The absolute
number of CD8þB8Rþ cells was plotted. (d) 5 106 pfu of modified vaccinia ankara was applied to TNFR1/ and WT mice by scarification. At indicated time
points, in vitro restimulation assay was performed to detect VV-specific IFN-g from spleens and ILNs. Error bars represent mean±SEM. n¼ 3–5 per group.
*Po0.05, **Po0.01, ***Po0.001. NS, not significant.
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radioresistant skin cells, as opposed to circulating BM–
derived cells, is the key factor associated with more vigorous
local virus replication and dissemination, and leads to the
development of larger skin lesions and satellite lesions in VV-
scarified TNFR1/ mice.
As the impaired cutaneous response to VV scarification of
TNFR1-deficient mice appeared to reflect a malfunction of
skin stromal cells, we explored potential mechanisms that
might lead to this susceptibility. Toward this end, we
performed immunohistochemical staining of mouse skin
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using side and forward scatter. Representative results of two independent experiments are shown. n¼3–5 per group.
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Figure 5. Impaired cutaneous response to vaccinia virus (VV) scarification of TNF receptor (TNFR)1/ mice is related to resident skin cells. WR-VV
was applied to bone marrow (BM)-reconstituted chimeric mice by scarification. (a) Lesion size and (b) virus load at day 12 were determined. (c) Green
fluorescent protein (GFP)-VV was applied to wild-type (WT) and TNFR1/ mice by scarification; H&E and anti-GFP antibody staining were used to identify
VV-infected cells (brown) at day 5. Bars: WT top¼ 100 mm, middle and bottom¼25 mm; TNFR1/ top¼100 mm, middle and bottom pairs¼10 mm. (d) Skin
samples from WR-VV-inoculated mice were harvested for measurement of CRAMP gene expression. Error bars represent mean±SEM. n¼4–5 per group.
*Po0.05, **Po0.01, ***Po0.001. NS, not significant.
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inoculated with VV-green fluorescent protein (GFP). Interest-
ingly, the degree of keratinocyte staining was similar in WT
and TNFR1/ mice. In contrast, VV-GFP was detected in
numerous dermal mesenchymal cells in the superficial and
deep layers of skin in TNFR1/mice while these areas were
devoid of staining in WT mice (Figure 5c).
Given the evidence that the critical cells responding to
TNF in this model are radioresistant, we entertained the
possibility that the increase in VV replication and dissemina-
tion observed in TNFR1/mice could be due to an inability
to upregulate innate antiviral mechanisms in response to VV
scarification. The antimicrobial protein cathelicidin (or
CRAMP in mice) has been shown to posess critical antiviral
activity against VV in both human and mouse skin. Murine
CRAMP knockout mice exhibited reduced ability to control
VV replication and dissemination in the skin (Howell et al.,
2004, 2006). We compared CRAMP gene expression in the
skin from WT and TNFR1/ mice, and found that 12 hours
following VV scarification, CRAMP gene expression was
B4-fold higher in the inoculated skin of WT mice than
TNFR1/ mice (Figure 5d). CRAMP gene expression was
low in distant skin of both groups at all observed time points.
These results suggest that the inability of skin stromal cells to
upregulate CRAMP in response to TNF stimulation may be
the fundamental defect in TNFR1-deficient mice.
DISCUSSION
In this study, we have shown that WT mice were able to
control VV replication in epidermis after scarification, and
that VV-specific T cells were generated and able to eliminate
VV by week 3. In the absence of TNFR1, VV was able to
infect a broader area of the skin, including epidermal,
dermal, and subcutaneous layers. T cells still developed
and were able to eliminate virus, but larger lesions and tissue
damage were observed. We went on to show that this
outcome in TNFR1/ mice is related to innate immune
mechanisms inherent in the skin, specifically in the skin
stromal cells and not hematopoietic cells, and is likely related
to the capacity of CRAMP to restrict VV dissemination.
TNF-a exerts its effects through binding to a pair of specific
receptors, TNFR1 and TNFR2 (Faustman and Davis, 2010).
We elected to perform our initial experiments in TNFR1/
mice because VV is commonly used to vaccinate humans by
skin scarification, and keratinocytes express almost exclu-
sively TNFR1. It has been reported that keratinocytes can
serve as a first line of defense following VV skin infection in
that they are less permissive to VV infection and replication
in vitro as compared with dermal fibroblasts and micro-
vascular endothelial cells (Liu et al., 2005). The epidermis of
normal skin contains low levels of TNF-a, while cutaneous
infection can greatly increase its synthesis and release from
keratinocytes (Kock et al., 1990; Nestle et al., 2009). One
explanation of our results is that disruption of the TNF-a/
TNFR1 pathway makes skin stromal cells more susceptible to
VV infection and leads to virus dissemination to dermal and
subcutaneous tissues. Reduced expression of the CRAMP
gene in the skin of TNFR1/ mice following VV scarifica-
tion supports this hypothesis.
Specifically, VV-specific Ab production and T-cell recruit-
ment and function did not prove to cause the impaired
cutaneous immune response to VV seen in TNFR1/ mice.
We did observe, however, that TNFR1/ mice did not
produce IgG1 subclass antibodies to VV, resulting in an
overall lower total VV-specific Ab titer. Similar defects in
primary antibody responses have been reported for
TNFR1/ mice exposed to Herpes Simplex virus (Lundberg
et al., 2007) and schistosome vaccine (Street et al., 1999).
These authors proposed that TNFR1/ mice have defects in
the follicular dendritic cell network and germinal center
formation in lymph nodes, which could affect Ab responses.
However, the overall humoral response was not significantly
different between TNFR1/ and WT mice in the first
2 weeks following scarification when the lesions differences
became manifest, and was sufficient to protect the mice from
subsequent lethal intranasal VV challenge. The results of
T-cell studies were more intriguing because TNFR1/ mice
showed an enhanced T-cell response to VV scarification as
compared with WT mice. TNF-a has been described as a
negative regulator of type 1 immune responses in other
infectious models. TNF-a/mice exhibited an uncontrolled
type I immune syndrome to pulmonary mycobacterium
infection (Zganiacz et al., 2004), and TNFR1/R2 double-
knockout mice displayed expanded viral-specific T cells in
the spleen following choriomeningitis virus (LCMV) infection
(Singh and Suresh, 2007). The mechanism by which TNF-a
regulates T-cell activity is not fully understood, and the
reason why TNFR1/ mice have enhanced type I responses
following VV scarification remains to be elucidated.
Our BM reconstitution experiments revealed that the
primary cells responding to TNF-a/TNFR1 signaling following
VV scarification to limit viral propagation are resident skin
cells, not hematopoietic cells. In preliminary studies, we have
also demonstrated that TNF-a/ mice develop large skin
lesions after VV scarification similar to those seen in
TNFR1/ mice (Supplementary Figure S3a online). We set
up BM reconstitution experiments with TNF-a/ mice to
further study this phenotype. Consistent with the results of
WT BM-TNFR1/ mice, WT BM-TNFRa/ mice
developed significantly larger skin lesions with higher virus
load at adjacent skin than the control WT BM-WT mice
following VV scarification. However, unlike TNFR1/
BM-WT mice, TNF-a/ BM-WT mice also developed
larger skin lesions with higher virus counts compared with
control chimeric mice (Supplementary Figure S3b and c online).
Therefore, while the target of TNF-a action is restricted to
skin stromal components, the source of TNF-a produced in
response to VV infection would appear to include both
hematopoietic cells and radioresistant skin elements. More
work is needed to understand the difference between
TNFR1/ mice and TNF-a/ mice upon VV scarification.
An important technical note for reconstitution experiments
involves Langerhans cells (LCs), long-lived BM–derived
epidermal dendritic cells. As LC are relatively radioresistant,
we may expect that a fraction of the epidermal LC present in
the chimeric mice should be of host origin (Poulin et al.,
2007). However, the fact that LC express predominantly
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TNFR2, and thus would not show altered function in
TNFR1/ mice, would indicate that altered LC function is
not the source of impaired cutaneous response in TNFR1/
mice or WT BM-TNFR1/ chimeric mice (Wang et al.,
1996).
To our knowledge, it has not been previously reported
that TNFR1 is essential for efficient and effective host defense
to cutaneous VV infection. Our results indicate that the
restriction of VV propagation by resident skin cells is the
specific point in the immune cascade that is defective in
TNFR1/ mice. We feel the data presented indicate that
TNF signaling has an important role in regulating local innate
immune responses in the skin and should be the target of
investigation in other models of skin infection. Understanding
the immune mechanisms of VV resistance in the skin and the
role of TNF-a will support the development of safer and more
effective vaccination strategies. Furthermore, these findings
may have important implications regarding the use of TNF-a
antagonists in the treatment of chronic inflammatory dis-
orders, which may present a currently unappreciated risk for
the development of eczema vaccinatum–like responses.
MATERIALS AND METHODS
Mice
All mice used have a C57BL/6 genetic background. TNFR1-deficient
(TNFR1/) mice, TNF-a–deficient (TNF-a/) mice, Thy1.2þ
CD45.2þ B6 mice, and Thy1.2þ CD45.1þ congenic B6 mice were
originally obtained from Jackson Laboratory (Bar Harbor, Maine),
and bred in a biosafety level 1 (BL-1) facility at Harvard Medical
School (HMS). All mice were handled in accordance with the
guidelines set out by the Center for Animal Resources and
Comparative Medicine at HMS.
Viruses and viral infection
Recombinant VV-expressing EGFP (GFP-VV) and WR-VV stocks
were expanded and titered by standard procedures (Liu et al., 2005).
Modified Vaccinia Ankara (MVA: ACAM3000MVA) was expanded
and titered using DF-1 cells (ATCC, Manassas, VA). The mice were
immunized with 5 106 pfu of VV or MVA by scarification at the
base of the tail as described (Tian et al., 2009). In some experiments,
C57BL/6 WT mice were injected intraperitoneally with 250 mg anti-
mouse TNF-a Ab (clone XT 3.11) or isotype control antibody (clone
HRPN) (Bio X cell, West Lebanon, NH) 1 hour before and every 3
days after WR-VV scarification. This dose was selected as the
standard for in vivo blockade of TNF-a in other mouse models
(Lundberg et al., 2007). Following VV scarification, lesions were
measured with a millimeter ruler every 2–4 days. For challenge
experiments, mice were anesthetized with isoflurane and inoculated
intranasally with 2 106 pfu of WR-VV as previously described (Tian
et al., 2009).
Quantitative PCR for determination of viral load
Viral load of various organs was determined by real-time PCR, as
previously described (Tian et al., 2009).
Measurement of VV-specific antibody
VV-specific antibody levels were determined at the indicated time
points by ELISA, as previously described (Tian et al., 2009).
In vitro restimulation assay
VV-specific cytokines were determined by in vitro restimulation
assay, as previously described (Tian et al., 2009).
Flow cytometry
Single-cell suspension from VV-inoculated tail skin was prepared as
previously described (Liu et al., 2010). To detect VV-specific CD8þ
T cells, single-cell suspensions from ILN, spleen, and skin of
immunized mice were stained with PE-conjugated B8R-pentamer
(Proimmune, Oxford, UK) as previously described (Freyschmidt et al.,
2010). To detect regulatory T cells, the cells were stained with
antibodies to mouse FoxP3 (APC) (eBioscience, San Diego, CA) as
well as CD4(FITC), CD25 (PE), and CD3 (PerCP) (BD Biosciences,
San Diego, CA) according to the manufacture’s protocol. For
intracellular IFN-g and Granzyme B staining, skin cells were first
stimulated with PMA and ionomycin (eBioscience) in the presence of
GolgiStop (BD Biosciences) for 5 hours, then stained with antibodies
to mouse IFN-g (APC) or Granzyme B (APC) in addition to CD8 (FITC),
B8R-pentamer (PE), and and B220 (PerCP) from BD Biosciences. The
stained cells were acquired on a FACSCanto (BD Biosciences) and
analyzed with FlowJo (Version 6.4.7, Tree star, Ashland, OR).
Immunohistochemistry
Inoculated skin was harvested from three to four mice per group at
each time point. Skin was preserved in formalin, embedded in
paraffin, sectioned, and stained with H&E, anti-CD3 antibody
(DAKO, Carpinteria, CA), and anti-GFP (Clontech, Palo Alto, CA)
as previously described (Tian et al., 2009).
BM chimeras
Adult congenic B6 (CD45.1) mice were lethally irradiated
(900–1,000Rad) and injected intravenously with 5–10 106 BM
cells from age- and gender-matched donor TNFR1/ (CD45.2) or
TNF-a/ (CD45.2) mice. In the case of WT BM-TNFR1/ or
WT BM-TNF-a/ chimeric mice, TNFR1/ or TNF-a/ mice
were used as recipients and reconstituted with BM cells from donor
congenic B6 (CD45.1) mice. Recipient B6 mice reconstituted with
BM from donor B6 mice that express different hematopoietic
markers (CD45.1 or CD45.2 accordingly) were used as controls.
The level of blood chimerism was determined as previously
described (Poulin et al., 2007). A 96–98% chimerism for all mice
can be achieved 8 weeks after BM reconstitution.
Real-time reverse transcriptase–PCR to detect CRAMP gene
expression
Total RNA was extracted from skin with RNeasy Lipid Tissue Mini
Kit (Qiagen, Valencia, CA). CRAMP gene expression was measured
as previously described (Howell et al., 2006). CT values for the
CRAMP gene were normalized to the reference gene cyclophilin A
as described previously (Liu et al., 2006). CRAMP gene expression in
the distant skin of WT mice was used as a baseline.
Statistics
The significance of observed differences between indicated groups
was assessed by an unpaired Student’s t-test. Tests were two-tailed
with a confidence interval of 95%. P-valueso0.05 were considered
significant. Statistical analyses were performed with Prism software
(v4.0, Graphpad Software, La Jolla, CA).
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